24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
OrbiMed
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
13:00
Brandlight helps enterprise marketers manage how AI recommends their brand
12:00
BlueGreen Water Technologies turns algae blooms into large-scale carbon removal
11:21
Taboola to acquire Dianomi for up to £27 million as it pushes deeper into finance advertising
11:00
BloomX replaces bees with robots to pollinate blueberries and avocados
More stories
Buzz
Most popular
Daily
Weekly
1
How an Israeli engineer went from Rafael to iPhone Portrait Mode and a $300 million OpenAI exit
2
The man who helped build Palo Alto’s Cortex is leaving the company
3
Serbia opens Israeli drone factory as defense ties with Elbit deepen
4
“Our next milestone will be a billion-dollar valuation”: MIND triples valuation to $300 million with $72 million Series B
5
Five months old, Noetive raises $41 million Seed to build AI for the physical economy
More news
OrbiMed
4 stories about OrbiMed
OrbiMed chooses against raising a third Israeli healthcare-dedicated fund
07.01.21
|
Meir Orbach
The investment firm raised a $307 million fund in 2016, but will not be founding another in a blow to the local ecosystem
Biological cancer treatment company Novellus raises $57 million
22.09.20
|
Tzally Greenberg
Novellus develops a drug that delays the development of a BRAF gene mutation created in cases of thyroid cancer and glioma cancer
OrbiMed Invests $16 Million in Derma Company Foamix
17.04.18
|
Lilach Baumer
Foamix is a clinical-stage company developing specialty foam-based treatments for skin conditions such as acne
Peter Thiel Invests in Israeli Biopharmaceutical Startup ChemomAb
04.12.17
|
Meir Orbach
ChemomAb develops an antibody treatment for inflammatory and fibrotic diseases